FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 342:1416-1429 May 11, 2000 Number 19 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article PubMed Citation

Soon after the acquired immunodeficiency syndrome (AIDS) was first described in 1981,^1,2,3,4 it became clear that opportunistic infections occurred with remarkable frequency and caused substantial morbidity and mortality among patients with AIDS. On the basis of a series of clinical trials, chemoprophylaxis to prevent initial episodes of certain opportunistic infections (primary prophylaxis) and subsequent episodes (secondary prophylaxis) became the standard of care. The success of highly active antiretroviral therapy (defined as combination antiretroviral regimens that include either a potent viral-protease inhibitor or a nonnucleoside reverse-transcriptase inhibitor) in reducing the incidence of AIDS-related opportunistic infections and consequent morbidity and mortality has . . . [Full Text of this Article]

Current Epidemiology of Opportunistic Infections

Immunologic Susceptibility to Infection

Prevention of Opportunistic Infections

Reduction of Exposure to Pathogens

Immunization

Primary Chemoprophylaxis

            P. carinii

            Toxoplasma gondii

            M. tuberculosis

            M. avium Complex

            Other Infections

Secondary Prophylaxis

Drug Interactions

Discontinuing Prophylaxis

Conclusions

Source Information

From the Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Md.

Address reprint requests to Dr. Masur at the National Institutes of Health, Clinical Center, Critical Care Medicine Department, 10 Center Dr., Bethesda, MD 20892-1662, or at hmasur@nih.gov.

References

This article has been cited by other articles:

• Saldanha, D., Gupta, N., Shenoy, S., Saralaya, V. (2008). Prevalence of opportunistic infections in AIDS patients in Mangalore, Karnataka. Trop Doct 38: 172-173 [Abstract] [Full Text]  
• Olley, B O, Bolajoko, A J (2008). Psychosocial determinants of HIV-related quality of life among HIV-positive military in Nigeria. Int J STD AIDS 19: 94-98 [Abstract] [Full Text]  
• Stupp, R., Hegi, M. E., Gilbert, M. R., Chakravarti, A. (2007). Chemoradiotherapy in Malignant Glioma: Standard of Care and Future Directions. JCO 25: 4127-4136 [Abstract] [Full Text]  
• Holst, P. J., Bartholdy, C., Stryhn, A., Thomsen, A. R., Christensen, J. P. (2007). Rapid and sustained CD4+ T-cell-independent immunity from adenovirus-encoded vaccine antigens. J. Gen. Virol. 88: 1708-1716 [Abstract] [Full Text]  
• Tosoni, A., Cavallo, G., Ermani, M., Scopece, L., Franceschi, E., Ghimenton, C., Gardiman, M., Pasetto, L., Blatt, V., Brandes, A. A. (2006). Is protracted low-dose temozolomide feasible in glioma patients?. Neurology 66: 427-429 [Abstract] [Full Text]  
• Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J.B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., Curschmann, J., Janzer, R. C., Ludwin, S. K., Gorlia, T., Allgeier, A., Lacombe, D., Cairncross, J. G., Eisenhauer, E., Mirimanoff, R. O., the European Organisation for Research and Treatme, (2005). Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. NEJM 352: 987-996 [Abstract] [Full Text]  
• Vestereng, V. H., Kovacs, J. A. (2004). Inability of Pneumocystis organisms to incorporate bromodeoxyuridine suggests the absence of a salvage pathway for thymidine. Microbiology 150: 1179-1182 [Abstract] [Full Text]  
• Chng, W. J., Tan, G. B., Kuperan, P. (2004). Establishment of Adult Peripheral Blood Lymphocyte Subset Reference Range for an Asian Population by Single-Platform Flow Cytometry: Influence of Age, Sex, and Race and Comparison with Other Published Studies. CVI 11: 168-173 [Abstract] [Full Text]  
• Roland, M. E., Lo, B., Braff, J., Stock, P. G. (2003). Key Clinical, Ethical, and Policy Issues in the Evaluation of the Safety and Effectiveness of Solid Organ Transplantation in HIV-Infected Patients. Arch Intern Med 163: 1773-1778 [Full Text]  
• Boyton, R J, Mitchell, D M, Kon, O M (2003). The pulmonary physician in critical care * Illustrative case 5: HIV associated pneumonia. Thorax 58: 721-725 [Full Text]  
• Pagani, J.-L., Chave, J.-P., Casjka, C., Glauser, M.-P., Bille, J. (2002). Efficacy, tolerability and development of resistance in HIV-positive patients treated with fluconazole for secondary prevention of oropharyngeal candidiasis: a randomized, double-blind, placebo-controlled trial. J Antimicrob Chemother 50: 231-240 [Abstract] [Full Text]  
• Hou, J. Y., Graham, J. E., Clark-Curtiss, J. E. (2002). Mycobacterium avium Genes Expressed during Growth in Human Macrophages Detected by Selective Capture of Transcribed Sequences (SCOTS). Infect. Immun. 70: 3714-3726 [Abstract] [Full Text]  
• Baggish, A. L., Hill, D. R. (2002). Antiparasitic Agent Atovaquone. Antimicrob. Agents Chemother. 46: 1163-1173 [Full Text]  
• Goldie, S. J., Kaplan, J. E., Losina, E., Weinstein, M. C., Paltiel, A. D., Seage III, G. R., Craven, D. E., Kimmel, A. D., Zhang, H., Cohen, C. J., Freedberg, K. A. (2002). Prophylaxis for Human Immunodeficiency Virus-Related Pneumocystis carinii Pneumonia: Using Simulation Modeling to Inform Clinical Guidelines. Arch Intern Med 162: 921-928 [Abstract] [Full Text]  
• Arno, P. S., Gourevitch, M. N., Drucker, E., Fang, J., Goldberg, C., Memmott, M., Bonuck, K., Deb, N., Schoenbaum, E. (2002). Analysis of a Population-Based Pneumocystis carinii Pneumonia Index as an Outcome Measure of Access and Quality of Care for the Treatment of HIV Disease. Am. J. Public Health 92: 395-398 [Abstract] [Full Text]  
• Piccinini, G., Comolli, G., Genini, E., Lilleri, D., Gulminetti, R., Maccario, R., Revello, M. G., Gerna, G. (2001). Comparative Analysis of Human Cytomegalovirus-Specific CD4+ T-Cell Frequency and Lymphoproliferative Response in Human Immunodeficiency Virus-Positive Patients. CVI 8: 1225-1230 [Abstract] [Full Text]  
• MAYAUD, C, CADRANEL, J (2001). AIDS and the lung in a changing world. Thorax 56: 423-426 [Full Text]  
• Currier, J. S., Williams, P. L., Koletar, S. L., Cohn, S. E., Murphy, R. L., Heald, A. E., Hafner, R., Bassily, E. L., Lederman, H. M., Knirsch, C., Benson, C. A., Valdez, H., Aberg, J. A., McCutchan, J. A. (2000). Discontinuation of Mycobacterium avium Complex Prophylaxis in Patients with Antiretroviral Therapy-Induced Increases in CD4+ Cell Count: A Randomized, Double-Blind, Placebo-Controlled Trial. ANN INTERN MED 133: 493-503 [Abstract] [Full Text]  
• Lederman, M. M., Valdez, H. (2000). Immune Restoration With Antiretroviral Therapies: Implications for Clinical Management. JAMA 284: 223-228 [Abstract] [Full Text]